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Correction of double strand DNA breaks proceeds in an
error-free pathway of homologous recombination (HR), which
can result in gene silencing of half of the DNA molecules caused
by action by DNA methyltransferase 1 (DNMT1) (Cuozzo, C.,
Porcellini, A., Angrisano, T., Morano, A., Lee, B., Di Pardo, A.,
Messina, S., Iuliano, R., Fusco, A., Santillo, M. R., Muller, M. T.,
Chiariotti, L., Gottesman, M. E., and Avvedimento, E. V. (2007)
PLoS Genet. 3, e110). To explore the mechanism that leads to
HR-induced silencing, a genetic screen was carried out based on
the silencing of a GFP reporter to identify potential partners.
DMAP1, a DNMT1 interacting protein, was identified as a
mediator of this process. DMAP1 is a potent activator of
DNMT1 methylation in vitro, suggesting that DMAP1 is a corepressor that supports the maintenance and de novo action of
DNMT1. To examine critical roles for DMAP1 in vivo, lentiviral
shRNA was used to conditionally reduce cellular DMAP1 levels.
The shRNA transduced cells grew poorly and eventually ceased
their growth. Analysis of the tumor suppressor gene p16 methylation status revealed a clear reduction in methylated CpGs in
the shRNA cells, suggesting that reactivation of a tumor suppressor gene pathway caused the slow growth phenotype. Analysis of HR, using a fluorescence-based reporter, revealed that
knocking down DMAP1 also caused hypomethylation of the
DNA repair products following gene conversion. DMAP1 was
selectively enriched in recombinant GFP chromatin based on
chromatin immunoprecipitation analysis. The picture that
emerges is that DMAP1 activates DNMT1 preferentially at sites
of HR repair. Because DMAP1 depleted cells display enhanced
HR, we conclude that it has additional roles in genomic stability.

DNA methylation is a post-replicative, covalent modification
of genomic DNA that is a stable epigenetic mark implicated in
growth homeostasis (1). Epigenetics is also important in a wide
variety of processes such as differentiation (1), X chromosome
inactivation (2), and genomic imprinting (3). Miscues in DNA
methylation may cause growth defects, genomic instability (4),
and cancer (5). In mammalian cells, DNA methyltransferases
primarily target CpG dinucleotides leading to transcriptional
repression most likely by generating chromatin that cannot
engage basal transcription factors, thereby silencing linked

genes. DNA methyltransferases are distinguished as either
maintenance or de novo methyltransferases, depending on their
preference for hemimethylated or fully methylated DNA,
respectively (6). DNA methyltransferase 1 (DNMT1),2 for example, is generally considered to maintain DNA methylation
patterns associated with DNA replication (7), and it has a stronger preference for hemimethylated DNA; however, this biochemical feature is not absolute because DNMT1 also acts on
unmethylated targets (8, 9). Additional evidence for de novo
activity of DNMT1 in chromatin at sites of homologous recombination has recently been proposed (10).
Defects in DNA methylation may lead to a growth advantage
in somatic cells when a tumor suppressor gene is silenced or
when an oncogene becomes activated, thereby selecting for a
malignant growth phenotype (11, 12). A complete understanding of somatic cells is an important yet challenging topic in
cancer. The problem is complex because it is most likely a rare
event that happens to single cells followed by selective outgrowth. Processes that reset methylation patterns may alter
gene expression leading to unregulated cell growth behavior.
Epigenetic reprogramming in somatic cells is not as well documented as it is during development when a genome wide erasure of epigenetic imprints takes place (13–17). It was recently
demonstrated that DNA repair proteins may mediate the process (18). Indeed, somatic cell reprogramming leading to pluripotency involves base excision repair pathways downstream of
the cytosine deaminases (19). These collective findings, in concert with the idea that methylation is linked to genome stability,
strongly implicate DNA damage pathways in epigenetic reprogramming. A number of prior reports suggest a relationship
between DNA repair, recombination, and gene silencing. Specifically, DNMT1 and proliferating cell nuclear antigen are
binding partners (20) that provide a means to recruit DNMT1
to DNA repair sites (21). Moreover, DNMT1 mutant mouse
cells are genetically unstable (22, 23), and in human cells, global
reductions in CpG methylation contribute to genome instability (24). Recently, demethylation pathways have been demonstrated that involve activities normally associated with base
excision repair (25). In addition, we reported a relationship
between DS DNA damage, homologous recombination (HR)
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and gene silencing in somatic mammalian cells using an HR
reporter system developed by Jasin and co-workers (26) by
analysis of methylation patterns of repaired DNA (10). Evidence was presented that short regions flanking the DS DNA
break were subject to epigenetic resets following HR repair
where one strand was completely demethylated and the opposite strand was overlaid with new methylation patterns. The
result was twin populations of cells (in an approximate 1:1
ratio) where GFP was either silenced (hypermethylated) or
expressed (hypomethylated). In the current work, an HR
model GFP reporter was used to examine other factors that
may be important in epigenetic reprogramming associated
with repair in human cells. The DNMT1 binding partner
DMAP1 was identified as a key participant in the silencing of
HR repair products.

EXPERIMENTAL PROCEDURES
Plasmids, Cell Culture, and Transient Transfections—Lentiviral vectors (shDMAP1-1 and shDMAP1-2) were purchased
from Open Biosystems (clone numbers TRCN0000021744 and
TRCN0000021745) (Huntsville, AL). pcHA-DMAP1 expressing HA-tagged full-length DMAP1was provided by Dr. Keith D.
Robertson (Medical College of Georgia, Augusta, GA). Wild
type HCT116 colon cancer cells were provided by Dr. Bert
Vogelstein (Johns Hopkins University, Baltimore, MD) and
grown in McCoy’s 5A with 10% fetal bovine serum. HeLa and
HO1 cells (HeLa cells containing a DR-GFP (10) stably integrated) were grown in RPMI 1640 supplemented with 10% fetal
bovine serum and periodically maintained in puromycin to
ensure retention of the transgene. The transfections were performed using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions.
Analysis of Homologous Recombination—HR assays were
performed as previously described (10, 26). Briefly, HO-1 cells
transduced with lentivirus expressing shRNAs against human
DMAP1 or control shRNA were transfected with pC␤ASce
expressing I-SceI endonuclease as well as pSV␤Gal (Promega,
Madison, WI). Typically, cells with 50% of confluency in
60-mm dishes were transfected with 2 g of pC␤ASce and 0.5
g of pSV␤Gal. Transfection efficiencies were over 60%. After
transfection, the cells were incubated for 4 days, and GFP-positive cells were analyzed by flow cytometry using FACSCalibur
and CellQuest software (BD Biosciences, San Jose, CA). Transfection efficiency was normalized by the ␤-galactosidase assay
system (Promega, Madison, WI).
Protein Extraction and Western Blot Analysis—To analyze
the protein expression, nuclear proteins were extracted and
prepared as follows. The cells were harvested and washed twice
with a hypotonic buffer (10 mM Hepes, pH 7.6, 1.5 mM MgCl2,
10 mM KCl, 1 mM DTT) followed by a 10-min incubation with
hypotonic buffer on ice. The cells were homogenized by 10
strokes with a tight fitting Dounce homogenizer, and the nuclei
were collected with centrifugation at 13,000 rpm, 4 °C for 30 s.
The nuclei were then suspended in a salt extraction buffer (20
mM Hepes, pH 7.6, 1.5 mM MgCl2, 10% glycerol, 0.2 mM EDTA,
1 mM DTT, 0.5 mM PMSF, 420 mM NaCl) and incubated for 30
min on ice. The nuclear fraction was collected by centrifugation
at 13,000 rpm, 4 °C for 30 min, and protein concentration was
NOVEMBER 26, 2010 • VOLUME 285 • NUMBER 48

measured with Bio-Rad protein assay reagent. Typically, 5–10
g of nuclear protein were run on SDS-PAGE, and after electrotransfer onto nitrocellulose, the membrane was probed with
the following antibodies: anti-DMAP1 (ab2848; Abcam, Cambridge, MA), anti-DNMT1 (N-16; Santa Cruz Biotechnology,
Santa Cruz, CA), and anti-lamin A/C (05–714; Millipore, Billerica, MA). The signal was developed using SuperSignal West
Dura kit (Thermo Fisher Scientific, Rockford, IL). The images
were captured using the ChemiGenius documentation system
(SynGene, Cambridge, UK).
In Vivo Activity of DNMT1—Assays to analyze in vivo activity
of DNMT1 were performed as described by Liu et al. (27).
Briefly, cells treated with 10 M of aza-dC for 1 h were lysed
with 1% sarkosyl in TE (10 mM Tris/HCl, pH 7.5, and 1 mM
EDTA). The viscous lysates were layered onto a step CsCl gradient followed by centrifugation at 35,000 rpm, 22 °C with
SW50.1 rotor for 20 h. The gradient was fractionated into
0.5-ml aliquots, and DNA fractions were pooled. DNA concentrations were determined by UV spectroscopy. Typically, three
DNA concentrations (0.5, 1, and 2 g) were placed on a slot blot
device, and the membrane was probed with the anti-DNMT1
antibody. Immune complexes were detected with SuperSignal
West Dura kit (Thermo Fisher Scientific), and images were captured using a ChemiGenius documentation system (SynGene,
Cambridge, UK).
In Vitro DNA Methylation Assays—In vivo DNA methylation
assay was performed as previously described (28). Briefly, the
methylation activity of DNMT1 was measured by the incorporation of tritiated methyl group from radiolabeled S-adenosyl3
L-[methyl- H]methionine (PerkinElmer Life Sciences) into a
double strand oligonucleotide substrate containing a single CpG
site with or without a methyl group on the top strand (5⬘-GAAGCTGGGACTTCGGCAGGAGAGTGCAA-3⬘, where the underlining denotes a single CpG site). Oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA).
Double strand oligonucleotides were annealed by mixing equal
amounts of complimentary oligonucleotides, heating to 95 °C
for 5 min, and cooling down to room temperature. Fully
duplexed substrate was verified by agarose gel electrophoresis.
The methylation reaction was carried out at a concentration of
0.5 M DNA, 0.5 Ci of S-adenosyl-L-[methyl-3H]methionine
and variable amounts of purified DNMT1 (Methylation, Ltd.,
Port Orange, FL) in methylation reaction buffer (20 mM Tris/
HCl, pH 7.5, 5 mM EDTA, 5 mM DTT, 1 mM PMSF, and 10%
glycerol) at 37 °C for 1 h. Purified DMAP1 or ETS1 (purified by
overexpression of his tagged proteins in E. coli) was added as
indicated in the figure legends. The reactions were terminated
by adding phenol/chloroform, and DNA was precipitated by
adding the same volume of isopropyl alcohol. The DNA pellet
was dissolved in TE buffer and spotted on glass fiber filter
(Whatman, Kent, UK). Radioactivity was determined using a
LS6500 scintillation counter (Beckman Coulter, Brea, CA).
RNA Extraction and Quantitative Real Time RT-PCR—Total
RNA was extracted with TRIzol reagent (Invitrogen) according
to the manufacturer’s instructions. Extracted RNA was quantified using a NanoDrop (Thermo Fisher Scientific). The cDNAs
were generated from 2 g of total RNA in a 25-l reaction
volume using Moloney murine leukemia virus reverse tranJOURNAL OF BIOLOGICAL CHEMISTRY

37631

DMAP1 in Repair-induced Silencing
scriptase and 0.5 g of random hexamer (Promega, Madison,
WI). Quantitative real time PCR was performed using Fast
SYBR Green Master Mix and a 7500 Fast Real time PCR
system (Applied Biosystems, Foster City, CA). The cDNA was
amplified with the following primers: DMAP1-A, 5⬘-ACGGAGCAATGTTCTTCCAC-3⬘; DMAP1-B, 5⬘-CAGGCACCTGCACAGTCTTA-3⬘; DNMT1-A, 5⬘-CAGCTCGAGGACCTGGATAG-3⬘; DNMT1-B, 5⬘-ACCAACTCGGTACAGGATGC3⬘; GAPDH-A, 5⬘-CTCTGCTCCTCCTGTTCGAC-3⬘; and
GAPDH-B, 5⬘-ACGACCAAATCCGTTGACTC-3⬘.
Genomic DNA Extraction and Bisulfite Sequencing—Genomic DNA was isolated from cells infected with lentivirus
expressing shRNA against DMAP1 using DNeasy blood and
tissue kit (Qiagen) according to the manufacturer’s instructions. Genomic DNA (2 g) was used for sodium bisulfite modification with EpiTect bisulfite kit (Qiagen) and carried out
using the commercially supplied kit protocol. Bisulfite-modified DNA (2 l) was amplified with primers for p16 promoter:
BS2-p16A, 5⬘-GAGGGGTTGGTTGGTTATTAGA-3⬘; and
BS2-p16B, 5⬘-TACAAACCCTCTACCCACCTAAAT-3⬘. Amplified DNA was subcloned into pGEM-T Easy Vector (Promega, Madison, WI), and 10 independent clones from lentivirus-infected cells were sequenced. Sequencing was performed
by GENEWIZ, Inc. (South Plainfield, NJ). Sequence analysis
and alignment were performed with BiQ Analyzer software
(29).
Chromatin Immunoprecipitation—HeLa cells carrying DRGFP were transfected with either empty vector or pC␤ASce in
the 100-mm dishes. After 24 h, the cells were transferred into
150-mm dishes and incubated for further 72 h. After incubation
for total 4 days, the cells were fixed with 1% formaldehyde in
culture media followed by neutralization with 0.1 M glycine in
1⫻ PBS. Chromatin was prepared by sonication, and ChIP
assays were performed using a ChIP-IT Express kit (Active
Motif, Carlsbad, CA). For the recovery of chromatin DNA, the
following antibodies were used: anti-DNMT1 (N-16; Santa
Cruz Biotechnology), anti-DMAP1 (ab2848; Abcam), and antiLexA (2–12; Santa Cruz Biotechnology). Anti-LexA antibody
was used as a negative control. After chromatin immunoprecipitation, purified DNA fragments were used for PCR. The
primers used for PCR were: rec, 5⬘-GAGGGCGAGGGCGATGCC-3⬘; unrec, 5⬘-GCTAGGGATAACAGGGTAAT-3⬘; and
reverse common, 5⬘-TGCACGCTGCCGTCCTCG-3⬘.
Purification of DMAP1—Human cDNA of DMAP1 was subcloned into pET-28a (EMD/Novagen, EMD Chemicals, Gibbstown, NJ). BL21 (DE3) Escherichia coli strain was used to produce His-tagged DMAP1 protein. Because DMAP1 was found
to form the inclusion body in the pilot experiment, denaturation condition was used for the purification. BL21 (DE3) transformed with pET-DMAP1 was induced with 0.5 mM of isopropyl ␤-D-thiogalactopyranoside for 4 h at 37 °C. After harvest,
bacterial pellet was resuspended in 10 ml of 1⫻ PBS and sonicated. Inclusion body was collected by centrifugation and
resuspended in the binding buffer containing 50 mM Na2HPO4,
pH 8.0, 0.3 M NaCl, 1 mM PMSF, and 7 M urea. After solubilization at room temperature for 30 min, the solution containing
inclusion body was centrifuged at 15,000 rpm, 4 °C for 30 min.
The supernatant containing His-tagged DMAP1 was removed
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and incubated with nickel-nitrilotriacetic acid-agarose beads
(Qiagen) at 4 °C overnight. The protein/bead mixture was
washed with wash buffer containing 50 mM Na2HPO4, pH 8.0,
0.3 M NaCl, 1 mM PMSF, 7 M urea, and 10 mM imidazole. Histagged DMAP1 was eluted with elution buffer containing 50
mM Na2HPO4 pH 8.0, 0.3 M NaCl, 1 mM PMSF, 7 M urea, and
250 mM imidazole. The peak fractions were pooled and diluted
into a solution with a concentration of 1 g/l. The protein
solution was dialyzed against 1⫻ PBS.
Surface Plasmon Resonance (SPR) Analysis—The dissociation constants for DMAP1 and oligonucleotide DNAs were
analyzed with a SR7000 SPR refractometer (Reichert, Depew,
NY) in binding buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 3
mM EDTA, and 0.01% Tween 20). All of the experiments were
performed at a flow of 10 l/min at 37 °C. Each experiment was
repeated four times, and the standard errors were determined.
Protein-DNA interaction was analyzed after oligonucleotide
DNAs (hemimethylated, fully methylated, or unmethylated)
were coupled on the neutravidin-coated gold sensor slides.
DNA (25 l of 100 nM) was injected for the immobilization, and
the same amount of purified DMAP1 protein with concentrations of 1, 10, 25, 50, and 100 nM was used for the kinetic analysis. Data analysis was carried out using the SCRUBBER-2 software (University of Utah).

RESULTS
Knockdown of DMAP1 Reduces HR Repair-dependent DNA
Methylation—The DR-GFP reporter system is composed of
two mutated GFP repeat elements, separated by the drug selection marker (puromycin N-acetyltransferse gene) (26). The first
cassette (GFP-I) contains a unique I-SceI site derived from the
BcgI recognition site, creating two in-frame stop codons,
thereby inactivating expression. The second cassette contains
partial internal coding sequence of wild type GFP spanning the
BcgI site that serves as donor sequence for HR. The DR-GFP
(Fig. 1A) provides a useful readout to evaluate the expression
status of the GFP following transfection with I-SceI plasmid.
The reporter is stably integrated into HeLa cells (HO-1 cells) as
a single integrant, and gene conversion produces two GFP
expression classes (10). The HR-L corresponds to cells that
express lower levels of GFP because of DNMT1 activity that
maps to I-SceI flanking sites. The DR-GFP system was used to
identify candidate genes that participate in post HR repair
silencing. DMAP1 is reported to be involved in genome stability, is a DNMT1 binding partner, and interacts with proliferating cell nuclear antigen/Caf-1 in DNA repair (30); therefore, we
asked whether DMAP1 is involved in HR-dependent DNA
methylation. Because DMAP1 is abundant in somatic cells (30),
we tested the effects of DMAP1 knockdown using lentiviral
shRNA. Two different constructs were evaluated, and both
showed reductions in DMAP1 mRNA levels (Fig. 1B). DMAP1
protein levels were similarly affected (see also Fig. 4B). The two
independent shRNA targeting sequences confirm that the
down-regulation of DMAP1 is not likely due to nonspecific
silencing associated with off target genes by the shRNAs
selected. Because DMAP1 physically interacts with DNMT1,
we were concerned that reducing DMAP1 might also affect its
cognate partner; however, RT-PCR and Western blotting conVOLUME 285 • NUMBER 48 • NOVEMBER 26, 2010
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FIGURE 1. HR repair-induced silencing using DR-GFP. A, HeLa DR-GFP construct (10, 26). HeLa cells containing a stably integrated copy of DR-GFP were
used in the analysis (HO-1 cell line). There are two mutated GFP cassettes,
separated by a puromycin selective marker. The 5⬘ cassette (GFP-I) has been
inactivated by the addition of an I-SceI site containing tandem in-frame stop
codons. The 3⬘ cassette (GFP-II) contains a partial (812 bp) internal GFP coding
sequence and is therefore inactivated by 5⬘ and 3⬘ truncations. The two cassettes are separated by 3.7 kb. After transfection with a plasmid encoding the
I-SceI, a unique double strand break induces homology-directed repair at the
GFP integrant. Cassette II (GFP-II) acts as a homology donor to convert GFP-I
into WT GFP in a short tract gene conversion event. Also shown are rec and
unrec primers. Note that both primer sets are designed to analyze only cassette I because cassette II lacks the sequence for a downstream (3⬘) primer
(because of 5⬘/3⬘ truncations of GFP). The rec and unrec primers are further
distinguishable at the bold nucleotide positions. B, HO-1 cells were infected
with lentivirus expressing either nonhairpin control (Mock) or shRNA against
DMAP1. Expression of DMAP1 mRNA was quantified using real time RT-PCR.
All of the data were normalized with GAPDH expression. C, analysis of HR-H
and HR-L expression classes in DMAP1 knockdown cells. After infection with
two shRNA lentiviruses or a mock (nonhairpin control), HO-1 were transfected
with I-SceI. After incubation for 4 days, GFP-positive cells were analyzed by
FACS and to determine the HR-H:HR-L ratios (using CellQuest software).
D, analysis of HR frequency was performed by comparing the mock shRNA
cells with shDMAP1 by PCR using the Rec primer (plus internal ␤-actin control) as previously described (10).

firms that DNMT1 expression was not significantly altered
(data for HeLa cells shown in Fig. 2C, and for colon cancer cells
see Fig. 4, A and B). We performed fluorescence-based HR
assays on I-SceI transfected and lentivirus-transduced cells. In
the controls, GFP-expressing cells showed the typical 1:1 ratio
between high (HR-H) and low expressing (HR-L) cells, which
differ in DNA methylation states (10). These data (Fig. 1C)
demonstrate that knocking down DMAP1 significantly
increases the HR-H and decreases the fraction of HR-L (low
expressors) without affecting the frequency of HR (Fig. 1D).
Moreover, expression of DNMT1 was not affected in the
DMAP1 knockdown cells (noted above); therefore, alterations
in expression cannot be due to variable amounts of total endogNOVEMBER 26, 2010 • VOLUME 285 • NUMBER 48

FIGURE 2. Growth behavior and influence of DMAP1 on endogenous
DNMT1. A, genome wide activity of endogenous DNMT1 using the ICM assay.
The in vivo activity of endogenous DNMT1 was measured in HeLa cells
infected with shRNA expressing lentivirus 2 days post-infection. The cells
were pulsed with 10 M of aza-dC for 1 h and rapidly lysed with 1% sarkosyl
followed by CsCl step gradient purification of genomic DNA as described
under “Experimental Procedures.” DNA fractions (1.7g/cc) were pooled, and
the DNA concentration was measured by absorbance at 260 nm. Either 0.5, 1,
or 2 g of genomic DNA were applied to nitrocellulose membrane using the
slot blot manifold. The membrane was then probed with anti-DNMT1 antibody. Because the DNA concentrations are fixed, and the amount of DNA is
constant per cell, the signals can be compared directly. The amount of
DNMT1 covalently bound to cellular DNA reflects the genome wide activity.
B, analysis of cell growth kinetics. After infection with the indicated lentiviruses (mock, diamonds; shRNA1-1, squares; shRNA1-2, triangles) and selection
with puromycin, HeLa cells were seeded at 2 ⫻ 103 cells/well in a 96-well
microtiter plate. At each time point, the cells were lysed with 0.6% Nonidet
P-40, 0.4% PicoGreen in 1⫻ PBS. Fluorescence was measured with Tecan
Genios plate reader with excitation at 485 nm and emission at 530 nm.
C, DMAP1 and DNMT1 mRNA levels. The cells were transduced with the indicated
DMAP1 viruses, and 18 days later, expression of DMAP1 and DNMT1 were measured using quantitative real time RT-PCR as described under “Experimental Procedures.” The data were normalized with GAPDH expression.
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enous DNMT1 protein. We previously found that that HR-L
(low expression class) was due to DNMT1 activity directed at
I-SceI flanking sequences after gene conversion (10). An
enrichment of HR-H would be expected to occur in the DMAP1
knockdown cells if DNMT1 action was inhibited.
Reduction in DMAP1 Reduces DNA Methylation by Endogenous DNMT1—We next considered the possibility that endogenous DNMT1 activity was influenced by alterations in
DMAP1 in our experiments. To assess global or genome wide
activity of DNMT1, we performed a catalytic trapping assay to
measure the total amount of endogenous DNMT1 methylation
using the ICM method (27). In this experiment, the cells are
pulsed with aza-dC (which does not alter HR frequency) (10),
and the resulting covalent DNA䡠DNMT1 complexes were purified by CsCl gradient centrifugation. Fixed amounts of genomic
DNA are probed with anti-DNMT1 antibody to determine the
amount of DNMT1 bound on a per genome basis (27). In the
control cells, covalent binding of DNMT1 was dependent upon
treatment with aza-dC as shown previously (27) (Fig. 2A). In the
knockdown cells, we observed a large reduction (40 – 60% in
different experiments) in the activity of the endogenous
DNMT1 on genomic DNA (Fig. 2A, compare rows 2, 4, and 6).
Also, we observed a gradual reduction in the growth rate of the
cells (Fig. 2B), and by day 4 the cells essentially stopped growing; therefore, DMAP1 influenced growth-related gene expression circuits possibly through global methylation. This is consistent with the in vivo DNMT1 trapping data showing overall
reductions in cellular methylation by DNMT1 in the transduced cells (Fig. 2A). As noted elsewhere (Figs. 1B and 4B)
reduced DNMT1 catalytic activity is not due to alterations in
total cellular DNMT1 protein in these experiments. Even as late
as 18 days post-transduction, expression of DNMT1 was not
diminished (based on RT-PCR) under conditions where
DMAP1 transcription was significantly repressed (Fig. 2C).
Taken together, the data suggest that DNMT1 activity in chromatin depends on DMAP1, and the slow growth phenotype is
caused by alterations in expression status of genes involved in
growth control circuits (for example hypomethylation of tumor
suppressor genes; see Fig. 4).
DMAP1 Enhances DNMT1 Activity in Vitro—The data in
Fig. 2A are based on short pulses with aza-dC to trap endogenous DNMT1 on genomic DNA in cells; however, we were
concerned that the slower growth of transduced cells (Fig. 2B)
might alter the incorporation of the hypomethylating drug
into the DMAP1 knockdowns. Others have demonstrated
DMAP1䡠DNMT1 complex with HDAC2 at replication foci
(31–33); therefore, to determine whether DMAP1 has the ability to directly modulate DNMT1 action, independent of other
factors, we performed in vitro DNA methylation assays with
purified DNMT1 and a target oligonucleotide containing a single CpG. Although DNMT1 has a strong preference for hemimethylated targets, it also performs de novo, as indicated with
HR silencing (10). In this experiment, both hemi- and unmethylated DNA substrates were examined. The data show that
DNMT1 activity is enhanced 2.5-fold by DMAP1 on hemimethylated DNA and ⬃1.5-fold on unmethylated DNA (Fig. 3).
Human ETS1 protein did not alter DNMT1 activity on either
hemi- or unmethylated targets (ETS1 is not a DNMT1 interac-
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FIGURE 3. Activation of DNMT1 activity by DMAP1. In vitro methylase
assays were performed using either unmethylated or hemimethylated 30-bp
oligonucleotides with 200 ng of purified DNMT1 with or without purified
DMAP1 (0, 200, and 400 ng, DMAP1 tested). As a nonspecific negative control,
purified ETS1 protein tested at the same concentration (200 and 400 ng).
A, the results are expressed as pmol of incorporation of Ado-Met, corrected
for backgrounds (minus DNMT1 reactions and reactions pretreated with proteinase K). To facilitate comparison of HM and unmethylated (UM) targets, the
data are presented relative to DNMT1 lacking any protein additions. *, p ⬍
0.05; statistical significance was determined using a Student’s t test. B, the
data presented as percentages of DNMT1 activity without DMAP1.

tive factor, and the oligonucleotide substrate does not contain
ETS1 binding sites). Because the primary amino sequence of
DMAP1 does not show any homology with catalytic domains
found in DNA methyltransferases, the elevation of DNA methylation should be attributed to the activity of DNMT1 (DMAP1
alone does not methylate DNA) (Fig. 3). The in vitro data are
consistent with the in vivo results (aza-dC trapping; Fig. 2A)
and confirm that DMAP1 stimulates DNMT1 activity and that
this stimulatory action on DNMT1 proceeds independently of
other cellular components; however, it is likely that other factors may acutely impact events in a chromatin context.
Reduced DMAP1 and Demethylation of the p16 Promoter—
The data thus far suggest that DMAP1 plays a supportive role in
DNMT1 action globally (Fig. 2A) and specifically in HR repair
chromatin locally. This result suggests that DMAP1 represents
a central component in DNMT1 regulation and can influence
VOLUME 285 • NUMBER 48 • NOVEMBER 26, 2010
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methylation in a specific fashion. The effects of DMAP1 shRNA
on inhibition of cell growth (Fig. 2) may be a consequence of
DNMT1 inhibition, resulting in hypomethylation of unknown
gene targets culminating in a slow growth phenotype. To test
this, we examined methylation of the p16 promoter, which is
silenced in HCT-116 (34). HCT-116 cells were transduced with
the shRNA lentivirus, and expression of DMAP1 was evaluated
by real time PCR. At 10 days post-transduction, the two independent shRNA constructs reduced DMAP1 expression by
⬃60 – 80% (Fig. 4A), and Western blots confirm down-regulation at the polypeptide level (Fig. 4B). As noted with the HO-1
cell line, knocking down DMAP1 expression did not alter
DNMT1 expression (see also Fig. 2C). The methylation status
of the ⬃500-bp region in p16 promoter was also analyzed (Fig.
4C) after infecting HCT116 cells with lentivirus expressing
shRNA, at days 10 and 18. Mock infected cells showed ⬃50% of
the methylation level consistently at days 10 and 18. The shDMAP1-1 knockdown cells displayed ⬃30% of reduction in
methylation level (⬃50% to ⬃20%). Interestingly, shDMAP1-2
showed little if any change at day 10; however, by day 18, methylation levels decreased to ⬃30% as cells slowed or stopped
growing. As a control, the cells were treated with 5 M aza-dC
for 7 days, which strongly affected cell growth. The region was
completely demethylated by aza-dC, and we noted that cell
division was strongly inhibited. These results suggest that
DMAP1 knockdowns ultimately cause hypomethylation of the
p16 promoter region over time. To examine the generality of
demethylation, we checked several DNA sequences that are
known to be highly methylated in HCT116 cells: AluSx, AluJ,
LINE1, TIMP-3, and VEGFR1 (data for LINE-1 and TIMP-3
shown in Fig. 4D). These highly methylated genomic DNA
regions did not show any change in DNA methylation pattern.
Among the genomic DNA sequences examined, only the p16
promoter was hypomethylated.
DMAP1 Is a DNA-binding Protein That Preferentially Binds
Hemimethylated DNA—DMAP1 is a co-repressor that forms a
complex with DNMT1 and targets replication foci in the S
phase (31). Mobility shift experiments demonstrated that
DMAP1 binds DNA in a non-sequence-specific manner (data
not shown), and we next asked whether DNA methylation status was important in DNA binding. For this analysis, we quantified DMAP1/DNA binding using SPR analysis to derive rate
constants, ka (association) and kd (dissociation), and from this
relationship (kd/ka), we determined the equilibrium binding
constant (KD). The KD value is the affinity binding constant that
represents complex life span; specifically, a lower KD value corresponds with a higher affinity (35, 36). These SPR experiments
were conducted with purified DMAP1 and unmethylated,
hemimethylated, or fully methylated 30-bp oligonucleotides
containing a single, centrally located CpG site. The KD values
therefore reflect the importance of a single or double methyl
group on opposing strands. The relative affinity of DMAP1 for
hemimethylated (HM) DNA (Table 1 and Fig. 5A) was 280-fold
greater than unmethylated DNA and 32-fold greater than fully
methylated DNA targets. The binding preference was therefore
hemimethylated ⬎ fully methylated ⬎ unmethylated. A KD
value in the low nanomolar range (HM DNA) corresponds to a
relatively long half-life for the complex. The prediction is that
NOVEMBER 26, 2010 • VOLUME 285 • NUMBER 48

FIGURE 4. Methylation of p16 in HCT116 cells. Wild type HCT116 colorectal
cancer cells were infected with lentivirus expressing shRNA (shDMAP1-1 and
shDMAP1-2 constructs directed to DMAP1) or control shRNA (mock). A, transcriptional activity of DMAP1 and DNMT1 was determined by quantitative
real time RT-PCR, and the data were normalized relative to GAPDH expression. B, analysis of polypeptide levels by Western blotting. Nuclear extracts
were prepared as described under “Experimental Procedures,” and equivalent protein loads were analyzed by SDS-PAGE gels followed by Western blotting using anti-DMAP1, anti-DNMT1, and anti-lamin A/C antibody probes.
C, bisulfite sequencing of p16 gene in mock, shDMAP1-1, shDMAP1-2, and
aza-dC (5 M). The cells were harvested for bisulfite analysis at 10 and 18 days
post-transfection. In the aza-dC-treated cells, bisulfite treatment was carried
out at 7 days only. D, bisulfite sequencing of LINE-1 and TIMP-3 genes.
Genomic DNA from either mock or shRNA-infected HCT116 cells was
extracted, sodium bisulfite-treated, and amplified using a suitable primer pair
for p16 genomic DNA (⫺119 to ⫹380, see “Experimental Procedures”). Amplified DNAs were subcloned into pGEM-T easy vector, and 10 independent
clones were sequenced. The sequences were analyzed using BiQ Analyzer
software (for p16) or QUMA software (LINE-1, TIMP-2. An open circle denotes a
unmethylated CpG dinucleotide; a closed circles denotes a methylated CpG
dinucleotide.

under such conditions, the majority of endogenous DMAP1
should be bound at HM sites in association with DNMT1. We
considered that in this case, ectopic addition of DMAP1 should
not influence endogenous DNMT1 methylation of genomic
DNA, if all of the HM DNA sites are already bound. To test this,
we transfected HO-1 cells with DMAP1 plasmid and tested the
activity of DNMT1 on genomic DNA using ICM. The cell
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TABLE 1
SPR affinity data
SPR data are from four independent experiments, and a representative tracing for all
DNA targets is shown in Fig. 5A. ka is a rate constant that corresponds to the on rate
value, whereas kd represents the off rate. The dissociation constant (KD) is derived
from kd/ka.
DNA
Unmethylated
Hemimethylated
Fully methylated

ka

kd

⫺1 ⫺1
M
s

s⫺1

1.75 ⫻ 109
1.86 ⫻ 108
1.51 ⫻ 106

2.02 ⫻ 103
7.77 ⫻ 10⫺2
2.0 ⫻ 10⫺1

KD
1.16 M (⫾ 5 M)
4.15 nM (⫾ 20 nM)
131.7 nM (⫾ 68 nM)

growth behavior was not affected by ectopic addition of
DMAP1 (not shown). The data show that the addition of excess
DMAP1 did not significantly alter global methylation by
DNMT1 (Fig. 5B). This suggests that endogenous DNMT1 is
sequestered with the endogenous DMAP1 and that additional
protein is not able to further impact cellular methylation
profiles.
To examine the molecular association in chromatin, we carried out ChIP experiments using PCR primer pairs that detect
either recombinant (rec) or nonrecombinant (unrec) GFP molecules (see Fig. 1 map); therefore, we could examine chromatin

FIGURE 5. DNA binding activity and localization of DMAP1 in recombinant HR chromatin. A, DNA binding activity of DMAP1 was analyzed using SPR
assay. Biotinylated hemimethylated, unmethylated, or fully methylated double strand oligonucleotide DNA were immobilized on the gold chip coated
with NeutrAvidin. Purified DMAP1 protein was applied to the chip at a concentration of 1, 10, 25, 50, and 100 nM (flow rate of 10 l/min). The KD values
shown were derived from kinetic parameters based on the relationship KD ⫽ kd/ka, where kd is the dissociation rate constant, and ka is the association
rate constant. The ka and kd rate constants (Table 1) were derived by nonlinear curve fitting of sensogram data at the concentrations indicated above.
A representative SPR trace is shown for each DNA target, and the analysis was repeated four times with different oligonucleotide and protein preparations. B, effects of overexpression of DMAP1 on endogenous DNMT1 activity. The ICM method, which measures the total amount of endogenous
DNMT1 trapped on genomic DNA (34), was used to examine the influence of high level expression of DMAP1 on global methylase activity mediated by
DNMT1. HCT-116 cells were transfected with vector (mock) or DMAP1 plasmid (2.5 g), and 48 h later, exponentially growing cells were incubated with
10 M aza-dC for 1 h and immediately lysed with sarkosyl. The indicated amounts of genomic DNA were spotted on a slot blot and probed with
anti-DNMT1 antibody. C, ChIP analysis. The molecular association between recombinant GFP, DMAP1, and DNMT1 in a chromatin context was analyzed
by chromatin immunoprecipitation assay. After transfection of either mock or I-SceI plasmid, the cells were formaldehyde-fixed and harvested. The
sonicated DNAs were mixed with antibodies as indicated. Final immunoprecipitated DNAs were amplified with Rec primers, which detects only the
recombinant GFP DNA. Anti-LexA antibody was used as a negative control. D, band intensity ratios of DMAP1:DNMT1 before HR (⫺ I-SceI) and after HR
(⫹ I-SceI) in unrecombined chromatin (unRec primers) and recombinant chromatin (Rec primers). The analysis was repeated in three independent
experiments (see Fig. 1A for details on primer construction).
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structures that exist before and after HR repair/gene conversion. The 5⬘ unrec primer will only amplify the nonrecombinant GFP molecules from Cassette I because the 3⬘ primer is
missing from Cassette II. The 5⬘ rec primer is based on the
converted BcgI sequence and only amplifies recombinant GFP
molecules (Fig. 1A). The data confirm that in the absence of
I-SceI, we did not detect any PCR products in the various ChIPs
in the absence of HR (Fig. 5C). We detected DNMT1 and
DMAP1 in the unrecombined GFP chromatin. There is evidence for transgene silencing (37), suggesting that that integrated DR-GFP is methylated by DNMT1 (which explains the
presence of the co-repressor, DMAP1). After HR (⫹I-SceI)
both DNMT1 and DMAP1 were in a complex specific to
recombined chromatin. Following HR, the unrecombined GFP
chromatin contained lower levels of DNMT1 and DMAP1;
however, analysis of DMAP1/DNMT1 ratios (from three
independent ChIP experiments) revealed that unrecombined
templates contained approximately half as much DMAP1 compared with DNMT1 (Fig. 5D); therefore, DMAP1 was preferentially enriched in post-HR GFP chromatin. A negative control
with the LexA antibody did not recover any DNA products.
Collectively, these data suggest a specific association between
DNMT1, DMAP1, and recombinant GFP chromatin generated
by HR repair.
DMAP1 Depletion and p16 Hypomethylation—An important question from these studies relates to the basis for selective
hypomethylation of the p16 gene (Fig. 4) given our evidence
suggesting a role in HR-specific events (Fig. 5). In other words,
why would DMAP1 depletion incite hypomethylation at a gene
that is not specifically damaged by I-Sce1? One possibility we
considered is that DMAP1, in addition to promoting DNMT1
silencing at sites of HR repair, might also be important in
genome stability. To address this, we examined DMAP1 in HR
repair using the HO-1 cell reporter system. In this experiment,
DMAP1 was depleted using shRNA (or in mock RNA controls)
in HR reporter cells before and after I-Sce1 transfection. The
mock infected cells displayed the expected levels of GFP
expression before and after I-Sce1 expression (10); however, in
the DMAP1 knockdown cells, significant levels of WT GFP
were detected in the absence and presence of I-Sce1 (Fig. 6, top
panel). This was also seen in the shDMAP1-2-treated cells (not
shown). This striking increase in the percentage of GFP suggests that depletion of DMAP significantly activates HR pathways in these cells, and because we detected a clear increase in
GFP positive cells even in the absence of I-Sce1 (Fig. 6, top
panel), we conclude that DMAP1 depletion stimulates HR as a
result of DS DNA breaks and genome instability. The HR-H
(high expressor) fraction was elevated in recombinant cells
because of low DNMT1 activity (see Fig. 2A) in cells lacking
DMAP1 co-repressor activity (Fig. 6, bottom panel). In support
of this, a recent report showed that DMAP1 depletion leads to
genome instability in mouse cells, in particular in a p53 minus
background (HO1 cells are p53 minus) (30). Moreover, DMAP1
knockdowns accumulate DS DNA breaks, are aneuploid, and
are highly tumorigenic in mice (30). These findings help explain
why the p16 gene is altered in DMAP1 knockdown cells. In this
case, DMAP1 depletion causes genome instability leading to
damage (and repair) of genes such as p16. The resulting DNA
NOVEMBER 26, 2010 • VOLUME 285 • NUMBER 48

FIGURE 6. Influence of DMAP1 depletion on HR frequency. Top panel, the
HeLa DR-GFP construct (10, 26) described for Fig. 1 (HO-1 cell line) was used in
this experiment. HO-1 cells were infected with lentivirus expressing either
nonhairpin control (Mock) or shRNA1-1 against DMAP1. After incubation for 4
days, the cells were transfected with either I-Sce1 or no I-Sce1 (negative control), and the percentages of GFP-positive cells were analyzed by FACS 4 days
later. Under these conditions, DMAP1 expression levels are reduced by 4 – 6fold (in different experiments, see Fig. 4), and cells display a slow growth
phenotype (Fig. 2). B, analysis of HR-H and HR-L expression classes in DMAP1
depleted cells following I-Sce1 transfection was carried out as described for
Fig. 1.

repair-based silencing is inhibited in DMAP1-depleted cells
leading to hypomethylation of HR repair sites (along with an
increase in HR-H expressor class). Because p16 is only partially
methylated in these cells (Fig. 4C), any DNA damage and repair
without the support of DMAP1 co-repressor could potentially
induce hypomethylation and p16 expression. Note that Line-1
and TIMP-3 are much less likely to suffer genetic instability in
the DMAP1 knockdown cells caused by repressed chromatin
associated with hypermethylated domains (Fig. 4D).

DISCUSSION
Here we demonstrate that DMAP1 participates in the epigenetic reprogramming that was previously shown to attend
homology-directed DNA repair (10). This means that DMAP1
acts a co-repressor in global maintenance methylation (31), as
well as cooperating with DNMT1 in epigenetic alterations associated with repair of DS DNA breaks. Mechanistically, it
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appears that DMAP1 has a strong binding preference for hemimethylated DNA and stimulates DNA methylation mediated
by DNMT1. DMAP1 stimulates maintenance as well as de novo
DNMT1 activity in vitro. The silencing of recombinant GFP
following HR was previously shown to involve DNMT1, based
on mouse ES cell DNMT1⫺/⫺ mutants and on ChIP experiments performed in human cell lines (10). HR repaired DNA is
hemimethylated, and subsequent outgrowth of cells yielded
two expression classes of GFP, a high (HR-H) and a low (HR-L)
group of cells that differ in DNA methylation status at DNA
sites flanking the I-SceI site. Depleting DMAP1 using shRNA
increased expression of the HR-H class (undermethylated, high
expression class), whereas the HR-L (low expressor) class was
reduced; however, HR frequency was not similarly affected.
This result is consistent with the biochemical data showing that
DMAP1 stimulates DNMT1 activity on hemi- and unmethylated DNA targets. We propose that in a chromatin setting,
DMAP1 provides support as a co-repressor for DNMT1, and in
DMAP1 limited cells, HR repaired GFP is hypomethylated as a
result of depletion of DMAP1. The end result is an overall
increase in GFP attended by a decrease in the HR-L (methylated) expression class.
DMAP1 in Repair Methylation—DMAP1 is a DNMT1 binding partner (31), and in vitro biochemical data (Fig. 3) confirm a
supportive role in maintenance and de novo methylation. To
extend these findings in vivo, we examined whether eliminating
DMAP1 would alter the ability of DNMT1 to act globally on the
genome, using a brief aza-dC pulse to trap the methylase on
genomic DNA (Fig. 2A) (27). This method gives an overview of
the genome wide activity of a specific methylase (DNMT1 in
this case). The results are consistent with the biochemical data
and show that DMAP1 promotes DNMT1䡠DNA covalent complexes. In the absence of DMAP1, the genome is hypomethylated, thereby leading to a growth reduction arising from reactivation of genes that negatively modulate growth (such as
tumor suppressor genes) (34). This was confirmed in two ways.
First, we demonstrated that DMAP1 knockdowns initially displayed a slow growth phenotype and eventually ceased growing
(Fig. 2B). Second, we found that the p16 gene was hypomethylated in the DMAP1 knockdown cells (Fig. 4C). Reactivation of
p16 would explain the growth phenotype we observe. Note that
we did not detect any changes in terminal restriction fragment
lengths using a telomere-specific probe,3 which suggests that
telomere erosion/repair was not involved. Moreover, hypomethylation cannot be attributed to a reduction in DNMT1
levels in the shRNA transduced cells, based on Western blots.
The more likely interpretation is that DNMT1 activity is
affected by limited DMAP1 availability, leading to less robust
methylation in these cells. The data suggest that DMAP1 has
multiple roles as a DNMT1 co-repressor because DNMT1 targets HR repair chromatin (10) and other repair sites most likely
through its proliferating cell nuclear antigen-binding domain
(21, 30).
DMAP1 Depletion, p16 Hypomethylation—The data suggest
that DMAP1 participates in HR repair silencing (based on DR-

3

G. E. Lee, J. H. Kim, M. Taylor, and M. T. Muller, unpublished observation.
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GFP reporter cells) and possibly in global methylation (based
on ICM (27) data); however, we propose that p16 hypomethylation in DMAP1 knock-outs (Fig. 4) is the collective result of
genome instability and co-repressor activity by DMAP1. We
show that depleting DMAP1 in HO-1 reporter cells containing
the DR-GFP cassette (Fig. 1) generated WT GFP protein in the
absence of I-Sce1-induced cleavages. Initially, we considered
this to be a background problem in our assay; however, the
observation is highly reproducible and was detected with both
shRNA-DMAP1 constructs but not in mock or scrambled RNA
controls. Moreover, in I-SceI-transfected HO-1 cells, HR repair
was significantly elevated as well. As expected, limiting DMAP1
resulted in hypomethylated GFP products (HR-H or high
expressor class). Collectively, these data indicate that DMAP1
plays a key role in genome stability, either by directly promoting
HR repair or by stimulating DNMT1 methylation events, which
also promotes genome stability (21, 22). Our data do not allow
us to discriminate between these related consequences of
DMAP1 depletion. In our previous work we proposed that DS
DNA breaks in general and HR repair sites in particular are
marked by discontinuous hypermethylation in a segment 3⬘ of
the DS break (10). Such hypermethylation marks would be
enhanced by the combined action of DMAP1 and DNMT1. A
striking hallmark of such hypermethylation events at breaks
sites is that roughly 50% of the sequenced alleles are hypermethylated. This can be seen in the WT p16 gene of HCT-116
cells (Fig. 4C, Mock), where roughly half of the sequences display hypermethylation; therefore, the p16 gene appears to have
the epigenetic features of a recombination product. We propose that in the absence of DMAP1, the methylation status is
reprogrammed by two related phenomena: first, DNA instability leads to elevated damage at chromatin-accessible regions of
the genome (p16 being one of these sites), and second, faithful
HR repair ensues, but without DMAP1 support, the p16 gene
loses methyl-CpG residues, and the gene reactivates, leading to
the slow growth phenotype we observe. Possibly as a result of
post-HR hypomethylation and low DMAP1, this cycle of chromosomal breakage, HR repair, and hypomethylation is
repeated, leading to an amplified outcome at selective genetic
loci. Thus, the p16 gene is particularly sensitive to DNA damage
and epigenetic reprogramming associated with DNA repair.
Although DNA damage may be random in the absence of
DMAP1, certain genetic loci will be hypersensitive to damage
(much in the way the DNase I hypersensitive regions allow nuclease access), and lacking co-repressor support, such regions are
repaired to give WT gene function but will be epigenetically reprogrammed for expression. Indeed, our findings may explain the efficacy of hypomethylating drugs in cancer therapy that selectively
reactivate tumor suppressor genes (38 –41).
Combining these observations with affinity binding data for
methylated DNA leads us to propose the model described in
Fig. 7. The two situations described (Fig. 7C, DMAP1 knockdown, and Fig. 7B, WT DMAP1) are based on previous reports
that DNMT1 may act as a de novo methylase to establish a
hemimethylated repair intermediate (which does not segregate) leading to twin populations of expression class (HR-H and
HR-L) in roughly equal proportions (10). This conclusion is
based on evidence for new methylation events that did not exist
VOLUME 285 • NUMBER 48 • NOVEMBER 26, 2010
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DMAP1, which retains DNMT1 at
the site of HR. Note that the KD values for DNMT1 for HM DNA are in
the micromolar range4; therefore,
DMAP1 is likely to play a central
role in assembly of the silencing
complex during or after HR. The
HR expressor classes are detected
following cell division and outgrowth leading to silenced daughter
cells (HR-L) and high expression
(unmethylated) daughter cells (HRH). DMAP1 also recruits or retains
DNMT1 at I-SceI flanking DNA
during subsequent S phase maintenance methylation schedules.
DMAP1 knockdown cells display
elevated genomic instability (Fig.
6A) and are also impaired in their
ability to strand-specifically methylate HR repaired products, which
leads to hypomethylation post-HR
and an increase in the HR-H population in the daughter cells. These
progeny cells would then display
slow growth as p16 expression
ramps up.
DMAP1 Preferentially Interacts
with HR Repair Chromatin—To
demonstrate a molecular association with recombinant GFP and
DMAP1 in chromatin post HR, we
carried out immunoprecipitation of
sheared, cross-linked chromatin
(ChIP). By using primer pairs that
interrogate separately rec and unrec
chromatin, we were able to deterFIGURE 7. Model describing DMAP1 role in silencing of HR repair. A, HO-1 cells contain the DR-GFP reporter, mine pre- and post-HR chromatin
and following expression of I-SceI, HR repair is initiated that recovers WT GFP sequences from the cassette II affiliation with each protein. That
donor sequence at the BcgI site. The methylation state of the reporter GFP prior to HR does not alter recombi- the presence of DMAP1 in chromanation frequency or silencing outcome after HR (10). Following HR repair, methylation patterns are either reset
or overlaid with new patterns. The I-SceI site is converted to a BcgI site as WT GFP is restored. B, in cells with tin fragments is specific for recomnormal DMAP1 levels, DMAP1 and DNMT1 are recruited as part the of the repair machinery (by proliferating cell binant chromatin comes from the
nuclear antigen or other repair factors) (21, 30). DNA flanking the I-SceI site is hemimethylated because of the
following pieces of evidence. First,
concerted action of DNMT1䡠DMAP1 on one strand (the opposing strand is protected, indicated by gray T
shapes). After cell division, two populations of cells are derived that differ in methylation state in flanking DNA the PCR signal was specific for
around the I-SceI site. The HR-H and HR-L are present at a 1:1 ratio. Because DMAP1 binds hemimethylated DNA DMAP1 antibody but negative with
with high avidity and poorly to unmethylated DNA, it is likely that DMAP1 recruits DNMT1 to promote conversion of hemimethylated to fully methylated DNA during the S phase; however, the daughter DNA strands heterologous control antisera. Secderived from the unmethylated parentals are not good DNMT1 targets because DMAP1 binds poorly to ond, DMAP1 antibody signals were
unmethylated templates. C, in DMAP1 knockdown cells, DNMT1 activity is reduced because of the low levels of clearly enriched using PCR primers
the DMAP1 co-repressor, which then hampers recruitment of DNMT1 to GFP recombinant chromatin. This
effectively elevates the level of the HR-H (high expression class) and reduces the fraction of the HR-L. Because that amplify the recombinant GFP
DMAP1 knockdowns also display genomic DNA instability (Fig. 6) (30), HR repair and methylation events are products generated in I-SceI transactivated at sites of DNA damage in the knockdown cells; however, in the absence of DMAP1, DNMT1 action is
fectants. Third, positive control
less robust, leading to hypomethylation at sites of HR repair.
anti-DNMT1 antibody yielded sigprior to HR; however, the possibility that epigenetic patterns nals from I-SceI positive cells but nothing from the I-SceI negare overlaid onto the original pre-HR template was also pro- ative counterparts. We conclude that DMAP1 is preferentially
posed (10). This suggests that DNMT1 methylation events are bound to HR chromatin and helps shape the final epigenetic
an admixture of de novo and maintenance methylation. In this
case, some degree of hemimethylation post HR exists (for
instance 5⬘ or 3⬘ regions that flank the I-SceI region) to recruit 4 G. E. Lee and M. T. Muller, unpublished data.
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expression status of the repaired template. In the ChIP experiments, the unrec primer without I-SceI represents silencing/
chromatin assemblies that exist prior to HR repair in Cassette II
(Fig. 1A). By comparing DMAP1 before and after I-SceI transfection, we could interrogate DMAP1 binding in the donor
sequence (Cassette II) before and after HR (Fig. 5D). There was
a slight but reproducible elevation in DMAP1 occupancy post
HR. In chromatin from ⫹I-SceI/rec primer ChIP, DMAP1
occupancy increased more than 2-fold, suggesting that DMAP1
is preferentially recruited to the HR repair complex. Because
this result is highly reproducible, the most reasonable interpretation is that DMAP1 is involved in HR repair-based silencing
outcomes. Given the rather extreme preference of DMAP1 for
hemimethylated DNA and that DNMT1 methylation is stimulated preferentially on HM DNA, we propose that DMAP1 is
important in events that occur after the primary process of HR
(as the GFP-positive cells enter the cell cycle and replicate).
Hemimethylated DNA, which appears downstream of the de
novo event (10), should be an attractive substrate for DMAP1
binding and co-repressor activity, in a fashion similar to that
proposed by Np95 (42, 43). Thus, our model would be that
during or following HR repair, DNMT1 re-establishes methylation marks over a short range of flanking sequences near the
I-SceI cleavage in a DMAP1-dependent fashion. Any resulting
hemimethylation regions would be high avidity sites for
DMAP1, which would then recruit and assist DNMT1 into
these chromatin domains. Further studies will be important to
identify key regulatory components that participate in HR
silencing; however, this work establishes a tractable model for
insight into rare epigenetic events associated with repair of
double strand DNA breaks.
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